• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/19/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Augmented Reality

  • 9:50 AM

    Company introduces video highlighting advanced features of M3000 in workplace ROCHESTER, N.Y., VUZI, /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart-Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets, is pleased to announce that the Company will showcase its CES 2016 Innovation awards winner, the new M3000 Smart Glasses, at CES 2017. The Company’s latest smart glasses product for enterprise and prosumer will be unveiled and

    Read more
  • 1:35 PM

    Companies will deliver enterprise smart glasses solutions in Asia-Pacific region ROCHESTER, N.Y., VUZI /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or the “Company”), a leading supplier of Smart Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets, is pleased to announce that NTT DATA Singapore is the latest company to join the VIP (Vuzix Industrial Partner) Program to deliver smart glasses solutions for enterprise in the Asia Pacific region. NTT Data Singapore provides

    Read more
  • Immune Therapeutics
    2:10 PM

    ORLANDO Fla., April 11, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.’s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang). The Economist Intelligence Unit (EIU) projects $166 billion in drug sales in China by 2017, providing a recognized market to  further growth.

    Read more
  • 3:04 PM

    FRAMINGHAM, MA– ARTH, (Marketwired – Mar 9, 2016) – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (“AC5™”), today announces that it has received an internationally recognized ISO quality certification, marking completion of a critical step for Arch in its plans to commercialize AC5. The certification, which was awarded by British Standards Institution Group America, Inc., attests that the Company’s quality management system complies with the requirements of ISO 13485:2003 for the

    Read more
  • 4:14 PM

    Company Also Announced the Submission of Lodonal(TM) Data for Review in Connection with the New Drug Application to NAFDAC for Use as an Immune Booster and Adjunct Treatment for Human Immunodeficiency Virus ORLANDO, FL, IMUN, / ACCESSWIRE / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) in

    Read more
  • 3:06 PM

    Company is Currently Preparing IND for New Cancer Immuno-Therapy Drug SAN DIEGO, February 24, 2016, RGBP /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing of this approach in cancer patients. Dr. Kesari is Director

    Read more
Public Wire Banner